Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Multiple myeloma gammopathies

Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

Leukemia volume 33, pages 565–566 (2019)Cite this article

Subjects

Barosi and Gale [1] judge the quality of evidence which supports the current guidelines that lenalidomide maintenance following autologous stem cell transplant (ASCT) for multiple myeloma (MM) is a standard-of-care. In 2017, the United States Food Drug Administration (FDA) and the European Medicines Agency (EMA) added to the label of lenalidomide the indication of maintenance treatment following ASCT for MM. This approval was based on the findings of three phase 3 randomized clinical trials (RCTs): CALGB 100104 [2], IFM 2005-02 [3] and RV-MM-PI-209 [4], which were designed with time to progression (TTP)/progression free survival (PFS) as the primary endpoint. All three studies met their primary endpoint with hazard ratios (HR) of 0.37, 0.50 and 0.47, respectively [2,3,4]. With additional follow-up, CALGB 100104 demonstrated a statistically significant overall survival (OS) benefit (HR 0.61, p = 0.0004) [5]. As none of these studies were powered to evaluate OS as the primary endpoint, a meta-analysis of the three studies using patient-level data was conducted, revealing a survival advantage with lenalidomide relative to placebo/observation (HR 0.75, 95% CI 0.63–0.90, p = 0.001; median OS: lenalidomide: not reached; placebo/observation: 86 months) [6]. Myeloma XI, a fourth RCT, reported increases in both PFS (HR 0.48, p < 0.0001) and OS (HR 0.69, p = 0.013) with lenalidomide maintenance relative to observation [7]. A meta-analysis incorporating all four of these RCTs revealed an overall hazard ratio for OS of 0.72 [7]. The National Cancer Comprehensive Network (NCCN) guidelines has included single-agent lenalidomide maintenance as the preferred maintenance regimen, listing it as category 1 (based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate) [8].

Barosi and Gale [1] utilize the GRADE [9] (Grading of Evidence, Assessment, Development and Evaluation) approach to evaluate the quality of evidence for the use of lenalidomide maintenance post-ASCT. They conclude that the IFM, CALGB and GIMEMA trials present a risk of bias from selective reporting, because the three studies did not report quality of life (QoL) or second PFS data. However, the CALGB and IFM studies were not designed to evaluate QoL and none of them included second PFS as a secondary endpoint. The presence of selective reporting biases should be based on whether or not the investigators report out their planned analyses, as reporting of unplanned analyses are fraught with dangers from lack of adequate power and unrecognized confounders.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Barosi G, Gale RP. Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma. Leukemia.

  2. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81.

    Article  CAS  Google Scholar 

  3. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–91.

    Article  CAS  Google Scholar 

  4. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.

    Article  Google Scholar 

  5. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4:e431–e42.

    Article  Google Scholar 

  6. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.

    Article  CAS  Google Scholar 

  7. Jackson G, Davies FE, Pawlyn C, Cairns D, Striha A, Hockaday A, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Blood. 2017;130:436.

    Google Scholar 

  8. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16:11–20.

    Article  Google Scholar 

  9. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–2.

    Article  Google Scholar 

  10. Sobrero AF, Pastorino A, Sargent DJ, Bruzzi P. Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors. Clin Cancer Res. 2015;21:1036–43.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA

    Sarah A. Holstein

  2. Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

    Vera J. Suman

  3. Department of Medicine, Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    Philip L. McCarthy

Authors
  1. Sarah A. Holstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vera J. Suman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip L. McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah A. Holstein.

Ethics declarations

Conflict of interest

SAH reports serving as an advisory board member for Celgene, Takeda and Adaptive Biotechnologies, and as a consultant for Celgene and GlaxoSmithKline, outside the submitted work. PLM reports receiving honoraria from Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda and Binding Site, research funding from Celgene, and has served on advisory committees/review panels/board membership for Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, Binding Site and Karyopharm outside the submitted work. VJS declares that she has no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holstein, S.A., Suman, V.J. & McCarthy, P.L. Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale. Leukemia 33, 565–566 (2019). https://doi.org/10.1038/s41375-018-0359-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0359-7

This article is cited by

Search

Advanced search

Quick links